Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Enterprise Value (2024 - 2025)

Historic Enterprise Value for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$65.6 million.

  • Prelude Therapeutics' Enterprise Value rose 5837.83% to -$65.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.6 million, marking a year-over-year increase of 5837.83%. This contributed to the annual value of -$137.7 million for FY2024, which is N/A changed from last year.
  • Prelude Therapeutics' Enterprise Value amounted to -$65.6 million in Q3 2025, which was up 5837.83% from -$124.8 million recorded in Q2 2025.
  • Prelude Therapeutics' Enterprise Value's 5-year high stood at -$65.6 million during Q3 2025, with a 5-year trough of -$206.0 million in Q1 2024.